Related Experiment Video
Updated: Jul 4, 2025
08:09
Isolation, Culture, and Imaging of Human Fetal Pancreatic Cell Clusters
Published on: May 18, 2014
14.4K
[Evolution of insulin therapy: past, present, future].
D V Kurkin1, D A Bakulin2, A I Robertus3
1Moscow State University of Medicine and Dentistry of A.I. Evdokimov.
Problemy Endokrinologii
|February 5, 2024
Summary
The discovery of insulin revolutionized diabetes mellitus treatment, transforming a fatal condition into a manageable one. Continuous advancements in insulin therapy have significantly improved patient quality of life over the past century.
Area of Science:
- Endocrinology
- Biochemistry
- Medical History
Background:
- The 100th anniversary of insulin discovery highlights its profound impact on diabetes mellitus management.
- Historically, diabetes was a rapidly fatal disease, particularly in children and adolescents.
- Insulin therapy has evolved from early animal-derived sources to sophisticated modern analogues.
Approach:
- This review chronicles the historical development and evolution of insulin therapy.
- It examines various generations of insulin, from early preparations to advanced analogues.
- The review also discusses emerging trends in insulin delivery and molecular development.
Key Points:
- Insulin's discovery by Banting, Best, and Collip saved millions of lives.
- Modern insulin analogues offer improved glycemic control and patient convenience.
- Ongoing research focuses on novel delivery systems and glucose-responsive insulin molecules.
Conclusions:
- Insulin therapy has dramatically improved the quality of life for individuals with diabetes over the last century.
- Research continues to advance insulin delivery methods and develop "smart" insulin with glucose-dependent action.
- The future of diabetes care involves more personalized and convenient insulin treatment options.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
197
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
197
01:16Insulin: Dosing Regimen and Adverse Effects
174
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
174
01:25Insulin: Biosynthesis, Chemistry, and Preparation
382
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
382
01:15Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
01:24Glucagon-like Receptor Agonists
323
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
323
01:22Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K